Sartorius Stedim Biotech S.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- René Fáber
- Full Time Employees
- 10,265
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Address
- Zone Industrielle Les Paluds Aubagne PAC France 13781
- IPO Date
- Aug 3, 2009
- CIK
- 0001794363
- Website
- sartorius.com
- Similar Companies
- Business
- Sartorius Stedim Biotech S.A. Sartorius Stedim Biotech S.A. is a leading international partner to the biopharmaceutical industry that provides equipment, consumables and services for the development, quality assurance and production of biologics, vaccines and other biotech medications. The company offers a comprehensive portfolio covering the entire bioprocess value chain, including cell line technologies, cell culture media, single-use bioreactors, tangential flow filtration systems, chromatography solutions, purification and concentration products for biological intermediates, single-use bags and systems for storage and transportation, as well as data analytics software for process modeling and optimization; it also supplies laboratory products such as analytical balances, pipettes and filtration systems for research and development in drug discovery, cell biology and molecular biology. Founded in 1978 as Stedim and merged in 2007 with Sartorius AG's biotech division to form the current entity, Sartorius Stedim Biotech S.A. is headquartered in Aubagne, France, with manufacturing and R&D sites, sales offices and subsidiaries in more than 30 countries across Europe, North America, Asia and other regions, employing around 9,900 to 10,600 people worldwide and generating approximately 2.8 billion euros in sales revenue in 2024. The company operates primarily through its Bioprocess Solutions segment focused on integrated solutions for upstream and downstream manufacturing in oncology, immunology, rare diseases and cell and gene therapies, complemented by a Lab Products & Services segment. Recent developments include strategic partnerships such as the 2025 alliance with Nanotein Technologies involving a minority investment of up to 3 million US dollars for exclusive distribution and joint development of NanoSpark immune cell activation reagents for cell and gene therapy, as well as a collaboration with Bio Usawa Biotechnology to enable biopharmaceutical manufacturing in Africa through technology transfer, process optimization and supply of bioprocessing equipment, media, buffers and consumables; Sartorius Stedim Biotech continues long-term investments in production capacity expansion, particularly in North America and Asia, alongside ongoing acquisitions of complementary technologies to enhance single-use solutions, automation and sustainability initiatives targeting an underlying EBITDA margin above 35 percent by 2028.
Sartorius Stedim Biotech S.A. (SRTOY) Q4 2025 Earnings Call Transcript
Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing
Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa
Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible's Unique Cell-Based mRNA Design and Manufacturing Platform
Sartorius, Sartorius Stedim Biotech shares jump after results beat
Sartorius Stedim Biotech S.A. (SDMHF) Q3 2024 Earnings Call Transcript
Sartorius Stedim Biotech S.A. (SDMHF) H1 2024 Earnings Call Transcript
Sartorius Stedim Biotech S.A. (SDMHF) Q4 2023 Earnings Call Transcript
10 stocks for investors looking for ‘wonderful companies at a fair price'
Sartorius Stedim Biotech S.A. (SDMHF) Q3 2023 Earnings Call Transcript
Sartorius Stedim Biotech S.A. (SDMHF) Q2 2023 Earnings Call Transcript
Sartorius, Sartorius Stedim shares fall after Polyplus acquisition
Sartorius Stedim Biotech S.A. (SDMHF) Q4 2022 Earnings Call Transcript